AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

AnHeart Therapeutics and Innovent Biologics, Inc. announced that the Center for Drug Evaluation of China’s National Medical Products Administration has accepted a second New Drug Application for taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor.